Ibrutinib Treatment of Relapsed CLL Following Allogeneic Transplantation: Sustained Disease Response and Promising Donor Immune Modulation
Biology of Blood and Marrow Transplantation - Netherlands
doi 10.1016/j.bbmt.2014.11.490
Full Text
Open PDFAbstract
Available in full text
Date
February 1, 2015
Authors
Publisher
Elsevier BV